VSTM (Verastem, Inc.) Earnings growth in current year

Official company branding of verastem.com (VSTM)

The speculative potential of Verastem, Inc. (VSTM) relies on the patent protection of its ovarian cancer therapy, which is reflected in the GURU.Markets terminal via the current YoY EPS growth rate. The 34.80 metric confirms the current level of efficiency. Verastem, Inc. (VSTM) is mitigating risks by developing inhibitors for rare tumors, yet it remains vulnerable to geopolitical disruptions in raw material supplies and the complexities of international scientific partnerships.

VSTM (Verastem) Earnings growth in current year history from 07/04/2022 to 11/12/2026

Comprehensive metric breakdowns and analytics for Verastem, Inc. (VSTM)

- share price and expert price forecast:
Price Verastem Oncology|VSTM - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Verastem Corp|VSTM - Total Company Value
- book capitalization data:
Accounting Value of a Share Verastem|VSTM - Book Capitalization|Market Value to Equity Ratio verastem.com|VSTM - Company Total Assets
- debt and liquidity details:
Debt to Capital Verastem, Inc.|VSTM - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio verastem.com|VSTM - Company Aggregate Debts|Debts to Book Value Verastem Corp|VSTM - Company Long-Term Debts|Company Short-Term Indebtedness Verastem|Intermediate Coverage Ratio verastem.com
- net income and valuation multiples indicators:
VSTM - Net Income|Future Net Profit Verastem, Inc.|VSTM - P/E Multiple|Future Price to Earnings Multiple Verastem Corp|VSTM - PEG Multiple|Company Value to EBITDA Verastem Corp|VSTM - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Verastem|VSTM - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth verastem.com|VSTM - Earnings per share growth in current year|Net earnings per share change forecast for next year Verastem, Inc.
Fundamental valuation:VSTM Verastem Oncology
Signature product of Verastem Corp

Investors use this metric to evaluate net earnings per share dynamics, which serves as an indicator of capital management efficiency and business scaling. The metric's calculation logic is based on a percentage comparison of the current EPS against the same value from the previous year, and tracking annual EPS growth at a value of 34.80 currently reflects the absence of commercial sales for Verastem, Inc. prior to the market launch of its premium oncology drugs.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Corp) - Earnings growth in current year|Earnings growth in current year Nuvalent Therapeutics|Earnings per share growth in current year Kymera Therapeutics (KYMR)|IDYA (ideayabio.com) - Earnings per share increase in current year|Earnings growth in current year ELVN (Enliven Therapeutics, Inc.)|Net earnings per share change in current year ORIC Pharmaceuticals Inc|Relay Pharma - Earnings growth in current year|Earnings per share growth rate in current year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Net earnings per share growth this year|GLUE: Net earnings per one share growth for the current year|CGEM (Cullinan Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Immuneering Corp IMRX|Earnings growth in current year CCCC|Black Diamond Therapeutics, Inc - Earnings per share growth this year|Repare Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year PMVP|KPTI: Net earnings per share growth this year|Propanc Biopharma Inc - Net earnings per one share growth for the current year|BGMS: Earnings growth in current year|Aadi Bioscience, Inc. - Earnings per share increase in current year|ALRN (Aileron Therapeutics Inc) - Earnings growth in current year|Earnings per share growth rate in current year Blueprint Medicines Corp BPMC|Earnings per share growth in current year GlycoMimetics, Inc. (GLYC)|SWTX (SpringWorks Therapeutics Inc.) - Earnings per share increase in current year